Dupont Capital Management Corp decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 86.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,144 shares of the biotechnology company’s stock after selling 7,025 shares during the quarter. Dupont Capital Management Corp’s holdings in Biogen were worth $358,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of the stock. Pathstone Family Office LLC acquired a new position in Biogen in the 1st quarter worth $102,000. Prentiss Smith & Co. Inc. lifted its holdings in Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock worth $104,000 after buying an additional 50 shares in the last quarter. Atlantic Trust LLC acquired a new position in Biogen in the 2nd quarter worth $114,000. Independent Portfolio Consultants Inc. lifted its holdings in Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock worth $123,000 after buying an additional 219 shares in the last quarter. Finally, Carroll Financial Associates Inc. lifted its holdings in Biogen by 1.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after buying an additional 6 shares in the last quarter. Institutional investors and hedge funds own 88.35% of the company’s stock.
Shares of Biogen Inc. (BIIB) opened at $310.44 on Monday. The firm has a market cap of $65,650.89, a P/E ratio of 14.38, a PEG ratio of 1.94 and a beta of 0.72. Biogen Inc. has a one year low of $244.28 and a one year high of $348.84. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.70 by $0.61. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $5.19 EPS. research analysts anticipate that Biogen Inc. will post 22.03 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/13/dupont-capital-management-corp-sells-7025-shares-of-biogen-inc-biib.html.
A number of brokerages have commented on BIIB. Vetr lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $298.30 price objective on the stock. in a report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) upgraded shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective on the stock in a report on Wednesday, August 16th. BMO Capital Markets reiterated a “hold” rating and issued a $318.00 price objective on shares of Biogen in a report on Tuesday, July 18th. Leerink Swann reiterated a “market perform” rating and issued a $338.00 price objective (up previously from $304.00) on shares of Biogen in a report on Wednesday, July 26th. Finally, BidaskClub upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Twelve research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $341.89.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.